Your browser doesn't support javascript.
loading
Association between Dipeptidyl Peptidase-4 Inhibitor Prescription and Erythropoiesis-Stimulating Agent Hyporesponsiveness in Hemodialysis Patients with Diabetes Mellitus.
Hasegawa, Takeshi; Zhao, Junhui; Bieber, Brian; Zee, Jarcy; Pisoni, Ronald L; Robinson, Bruce M; Hanafusa, Norio; Nangaku, Masaomi.
Afiliação
  • Hasegawa T; Showa University Research Administration Center (SURAC), Showa University, Tokyo, Japan.
  • Zhao J; Division of Nephrology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.
  • Bieber B; Department of Hygiene, Public Health, and Preventive Medicine, Graduate School of Medicine, Showa University, Tokyo, Japan.
  • Zee J; Center for Innovative Research for Communities and Clinical Excellence, Fukushima Medical University, Fukushima, Japan.
  • Pisoni RL; Anemia Working Group of the Japan Dialysis Outcomes and Practice Patterns Study (J-DOPPS), Osaka, Japan.
  • Robinson BM; Arbor Research Collaborative for Health, Ann Arbor, Michigan, USA.
  • Hanafusa N; Arbor Research Collaborative for Health, Ann Arbor, Michigan, USA.
  • Nangaku M; Arbor Research Collaborative for Health, Ann Arbor, Michigan, USA.
Kidney Blood Press Res ; 46(3): 352-361, 2021.
Article em En | MEDLINE | ID: mdl-33887741
ABSTRACT

INTRODUCTION:

Dipeptidyl peptidase-4 (DPP-4) has been hypothesized to improve responsiveness to erythropoiesis-stimulating agent (ESA). We aimed to describe the trend in DPP-4 inhibitor prescription patterns and assess the association between DPP-4 inhibitor prescription and ESA hyporesponsiveness (eHypo) in Japanese hemodialysis (HD) patients with diabetes mellitus (DM).

METHODS:

We analyzed data from the Japan Dialysis Outcomes and Practice Patterns Study phase 4-6 (2009-2017) on patients with DM who underwent HD thrice per week for at least 4 months. The primary exposure of interest was having a DPP-4 inhibitor prescription. The primary analysis outcomes were a binary indicator of eHypo (mean hemoglobin <10 and mean ESA dose >6,000 units/week over 4 months) and the natural log-transformed ESA resistance index (ERI). We used conditional logistic regression to compare within-patient changes in eHypo before and after initial DPP-4 inhibitor prescription. We used linear generalized estimating equation models to compare continuous ERI outcomes while accounting for within-patient repeated measurements with an exchangeable correlation structure.

RESULTS:

There was a monotonic increase in DPP-4 inhibitor prescription according to study year up to 20% in 2017. Moreover, 12.8% of patients with a DPP-4 inhibitor prescription were ESA hyporesponsive before the initial DPP-4 inhibitor prescription. After DPP-4 inhibitor prescription, the odds of eHypo and mean log-ERI remained unchanged in the whole cohort of our study. The interaction analysis of DPP-4 inhibitor and sideropenia showed that DPP-4 inhibitors attenuated eHypo in the patients without iron deficiency.

CONCLUSION:

Our findings indicate a recent increase in DPP-4 inhibitor prescription among Japanese HD patients with DM. DPP-4 inhibitors could improve ERI in patients undergoing HD without iron deficiency.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diálise Renal / Diabetes Mellitus / Inibidores da Dipeptidil Peptidase IV / Hematínicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Kidney Blood Press Res Assunto da revista: NEFROLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diálise Renal / Diabetes Mellitus / Inibidores da Dipeptidil Peptidase IV / Hematínicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Kidney Blood Press Res Assunto da revista: NEFROLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão